ArticleAmerican journal of hematology2023
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Article in American journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 78 citations in OpenAlex.
- A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients.Cancer research and treatment · 2024Trial
- Renal amyloidosis prediction in kidney disease patients accompanied by monoclonal gammopathy.British journal of haematology · 2026Article
- IgM-C4d Complex Causes the Inaccurate Measurement of Serum Uric Acid Levels via the Uricase Method.Current issues in molecular biology · 2026Article
- Genetic and clinical insights into the coexistence of multiple myeloma and diffuse large B cell lymphoma from a case report and systematic review with bioinformatics analysis.Discover oncology · 2026Article
- Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions.International journal of molecular sciences · 2026Review
- Multiomics integration of serum proteome and autoantibody profiles reveals diagnostic and prognostic biomarkers in glioma.Journal of neuro-oncology · 2026Article
- A real-world 10-year follow-up analysis of survival and safety of CD20-targeted therapy in patients with Waldenstrom macroglobulinemia.Frontiers in oncology · 2026Article
- Coexisting Waldenström Macroglobulinaemia and Alveolar Echinococcosis Presenting with Chylothorax that Resolved on Treatment: A Diagnostic and Therapeutic Challenge.European journal of case reports in internal medicine · 2026Article
- Zanubrutinib-Induced Acneiform Rash in a Patient With Waldenstrom's Macroglobulinemia.Case reports in medicine · 2026Article
- Cystoid Macular Edema Secondary to Hyperviscosity Syndrome in Waldenström Macroglobulinemia: A Case Report of Multimodal Treatment Response and the Adjunctive Role of Acetazolamide.The Kaohsiung journal of medical sciences · 2025Article
- Transformation and survival in patients with Waldenström macroglobulinemia: a population-based study.Discover oncology · 2025Article
- Treatment of Anti-myelin-associated Glycoprotein Neuropathy with Tirabrutinib and a 3-year Follow-up.Internal medicine (Tokyo, Japan) · 2025Article
- Cardiac light chain amyloidosis secondary to Waldenström's macroglobulinemia: A case report and review.Experimental and therapeutic medicine · 2025Article
- [Transformation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia into diffuse large B-cell lymphoma: five cases report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Generalized edema with acute renal failure in a patient with diabetes.The Korean journal of internal medicine · 2025Article
- Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review.JAMA internal medicine · 2025Review
- Signalling by co-operative higher-order assembly formation: linking evidence at molecular and cellular levels.The Biochemical journal · 2025Review
- Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.Nature communications · 2025Article
- Background and Clinical Features of a Unique and Mysterious Autoinflammatory Disease, Schnitzler Syndrome.International journal of molecular sciences · 2025Review
- A Rare Case of Pyoderma Gangrenosum Pointing to Waldenström Macroglobulinemia.Case reports in oncological medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
disease overviewWaldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. DIAGNOSIS: Presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients and is found in most IgM MGUS patients. MYD88 is not required for the diagnosis. RISK STRATIFICATION: Age, hemoglobin level, platelet count, β RISK-ADAPTED THERAPY: Not all patients who fulfill WM criteria require therapy; these patients can be observed until symptoms develop. Rituximab-monotherapy is inferior to regimens that combine it with bendamustine, an alkylating agent, a proteosome inhibitor, or a BTK inhibitor. The preferred Mayo Clinic induction is either rituximab and bendamustine (without rituximab maintenance) or zanubrutinib. MANAGEMENT OF REFRACTORY DISEASE: Bortezomib, cyclophosphamide, fludarabine, thalidomide, everolimus, Bruton Tyrosine Kinase inhibitors, carfilzomib, lenalidomide, bendamustine, and venetoclax have all been shown to have activity in relapsed WM. Given WM's natural history, the reduction of therapy toxicity is an important part of treatment selection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.